Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States - Lip, G YH; Pan, X; Kamble, S (Int J Clin Pract, 2016)
, et al.